Results 31 to 40 of about 64,446 (303)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism [PDF]

, 2013
BACKGROUND: Direct oral anticoagulants that target a single coagulation factor have been developed as an alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive non-inferiority margins suitable
Anthonie WA Lensing, Martin H Prins
core   +1 more source

Use of New Oral Anticoagulants/ Direct Oral Anticoagulants in Malignant Patients [PDF]

Cureus, 2020
Vitamin K antagonists are being used in the last five decades as an effective anticoagulant. However, for the past few years, new oral anticoagulants (NOACs) have been introduced as newer anticoagulant agents, which are gradually replacing the previously used vitamin K antagonist.
Khan, Yusra, Zaidi, Syed Owais, Razak, Bibi S, Zaki, Mariann, Malik, Bilal Haider   +4 more
openaire   +2 more sources

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol

Systematic Reviews, 2019
Background and purpose Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in ...
Gauruv Bose, Justin Graveline, Vignan Yogendrakumar, Dean Fergusson, Dar Dowlatshahi   +4 more
doaj   +1 more source

The relationships between vitamin K and cognition: a review of current evidence [PDF]

, 2019
Vitamin K is a fat-soluble nutrient discovered in 1935 and its role in blood coagulation has been thoroughly explored. In recent years, studies conducted in vitro and on animals highlighted vitamin K involvement in brain cells development and survival ...
Alisi, Ludovico, Cafolla, Arturo, Cao, Roberta, Caramia, Francesca, Cartocci, Gaia, De Angelis, Cristina, Fiorelli, Marco, Librando, Aloisa   +7 more
core   +2 more sources

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants

Research and Practice in Thrombosis and Haemostasis, 2022
Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromboplastin time and dilute Russell's viper venom time ...
Emmanuel J. Favaloro, Leonardo Pasalic
openaire   +3 more sources

Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution

Медицинский совет, 2021
The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina   +3 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Safety and differences between direct oral anticoagulants and vitamin K antagonists in the risk of post-traumatic intrathoracic bleeding after rib fractures in elderly patients

Emergency Care Journal, 2021
Closed chest traumas are frequent consequences of falls in the elderly. The presence of concomitant oral anticoagulant therapy can increase the risk of post-traumatic bleeding even in cases of trauma with non-severe dynamics. There is limited information
Gianni Turcato, Arian Zaboli, Andrea Tenci, Giorgio Ricci, Massimo Zannoni, Christoph Scheurer, Anton Wieser, Antonio Maccagnani, Antonio Bonora, Norbert Pfeifer   +9 more
doaj   +1 more source

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]

, 2014
Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Turpie, AG, van Eickels, M   +6 more
core   +2 more sources

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)

Biomedicines, 2021
The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies.
Claire Dunois
doaj   +1 more source